ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent research by Iralde-Lorente et al. [124] has identified phosphate-containing compounds as potential inhibitors of the 14-3-3/c-Abl protein–protein interaction (PPI), a pathway implicated in the pathogenesis of chronic myeloid leukemia (CML).